Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cairns, A. P.
Right arrow Articles by Taggart, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cairns, A. P.
Right arrow Articles by Taggart, A. J.
Related Collections
Right arrow Osteoarthritis and Cartilage
Right arrow Education
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2003; 42: 188-189
© 2003 British Society for Rheumatology

Letters to the Editor

Tumour necrosis factor inhibitors: maximizing patient safety

A. P. Cairns and A. J. Taggart

Department of Rheumatology, Musgrave Park Hospital, Stockman's Lane, Belfast, BT9 7BJ, Northern Ireland

The first 10% of the full text of this article appears below.

SIR, The tumour necrosis factor {alpha} (TNF-{alpha})-inhibiting drugs infliximab and etanercept have revolutionized the management of severe rheumatoid arthritis and other inflammatory arthropathies. By blocking TNF-{alpha} they exert potent immunosuppressive effects in a group of patients already at increased risk . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
S. A. Wright and A. J. Taggart
Pneumococcal vaccination for RA patients on TNF-{alpha} antagonists
Rheumatology, April 1, 2004; 43(4): 523 - 523.
[Full Text] [PDF]